Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback